Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Chronic hyperglycemia impairs insulin action, resulting in glucotoxicity, which can be ameliorated in animal models by inducing glucosuria with renal glucose transport inhibitors. Here, we examined whether reduction of plasma glucose with a sodium-glucose cotransporter 2 (SGLT2) inhibitor could improve insulin-mediated tissue glucose disposal in patients with type 2 diabetes. Eighteen diabetic men were randomized to receive either dapagliflozin (n = 12) or placebo (n = 6) for 2 weeks. We measured insulin-mediated whole body glucose uptake and endogenous glucose production (EGP) at baseline and 2 weeks after treatment using the euglycemic hyperinsulinemic clamp technique. Dapagliflozin treatment induced glucosuria and markedly lowered fasting plasma glucose. Insulin-mediated tissue glucose disposal increased by approximately 18% after 2 weeks of dapagliflozin treatment, while placebo-treated subjects had no change in insulin sensitivity. Surprisingly, following dapagliflozin treatment, EGP increased substantially and was accompanied by an increase in fasting plasma glucagon concentration. Together, our data indicate that reduction of plasma glucose with an agent that works specifically on the kidney to induce glucosuria improves muscle insulin sensitivity. However, glucosuria induction following SGLT2 inhibition is associated with a paradoxical increase in EGP. These results provide support for the glucotoxicity hypothesis, which suggests that chronic hyperglycemia impairs insulin action in individuals with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Long-term effects of sodium-glucose transport protein 2 inhibitors (SGLT2i) might enhance insulin sensitivity, thereby mitigating muscle catabolism and influencing the quality and functionality of the skeletal muscle.30,31”
From Imaging of Sarcopenia in Type 2 Diabetes Mellitus (2024) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425 · cited 2×
“After the start of insulin, no glucose was infused until the plasma glucose concentration declined to 100 mg/dl, at which level it was maintained by the adjustment of a variable glucose infusion based on the negative feedback principle (27).”
Self-citationDeFronzo, R. A., Jacot, E., Jequier, E., Maeder, E., Wahren, J., & Felber, J. P. (1981) · Diabetes · doi:10.2337/diab.30.12.1000 · Cited by 1,770 · cited 1×
“Since >80% of insulin-mediated glucose disposal during the euglycemic insulin clamp takes place in skeletal muscle (16), these results indicate that lowering the plasma glucose concentration in T2DM significantly improves muscle insulin resistance and are consistent with a glucotoxic effect of chronic hyperglycemia to…”
Self-citationMeasurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816 · cited 1×
“After drug administration and during the insulin clamp, nonsteady-state conditions for 3-3 H-glucose–specific activity prevail and the rate of glucose appearance ( R a ) was calculated with Steele’s equation (28).”
Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812 · cited 1×
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citationRossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Self-citationRossetti, L., Giaccari, A., & DeFronzo, R. A. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.610 · Cited by 770
Self-citationDeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515 · cited 1×
“Because of the close relationship between EGP (primarily reflects liver) and the fasting plasma glucose concentration (17), the decrease in FPG brought about by dapagliflozin would be expected to be associated with a decrease in HGP.”
Self-citationBanting Lecture 1997. Control of glucose uptake and release by the liver in vivo.
Cherrington, A. D. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1198 · Cited by 502
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443 · cited 1×
“…the impact of chronic hyperglycemia on insulin sensitivity in individuals with T2DM, we examined the effect of lowering the plasma glucose concentration on whole body insulin sensitivity by inhibiting renal sodium-glucose cotransport with dapagliflozin (15) using the insulin clamp technique.”
Self-citationDose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling
Belfort, R., Mandarino, L., Kashyap, S., Wirfel, K., Pratipanawatr, T., Berria, R., DeFronzo, R. A., & Cusi, K. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1640 · Cited by 404 · cited 1×
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citation
Research works printed but not linked: 1
- Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia. 1994;37(10):1025-1035. · DOI · Paper page
Cited by
Items 101–200 of 789
Garg, S. K., Peters, A. L., Buse, J. B., & Danne, T. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0246 · Cited by 108
“21,22 SGLT2 inhibition also augments preproglucagon gene expression by acting directly on SGLT2 receptors in pancreatic alpha cells.”
Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes
Sugiyama, S., Jinnouchi, H., Kurinami, N., Hieshima, K., Yoshida, A., Jinnouchi, K., Nishimura, H., Suzuki, T., Miyamoto, F., Kajiwara, K., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.40873 · Cited by 107
SGLT2 Inhibitors: Benefit/Risk Balance
Scheen, A. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0789-4 · Cited by 119
Brown, E. E., Rajeev, S. P., Cuthbertson, D. J., & Wilding, J. P. H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13650 · Cited by 117
Terasaki, M., Hiromura, M., Mori, Y., Kohashi, K., Nagashima, M., Kushima, H., Watanabe, T., & Hirano, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143396 · Cited by 107
“Previous studies demonstrate that a SGLT2i improved insulin sensitivity in patients with type 2 diabetes [29].”
Perry, R. J., Rabin-Court, A., Song, J. D., Cardone, R. L., Wang, Y., Kibbey, R. G., & Shulman, G. I. (2019) · Nature Communications · doi:10.1038/s41467-019-08466-w · Cited by 105
Wu, P., Wen, W., Li, J., Xu, J., Zhao, M., Chen, H., & Sun, J. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0958-2441 · Cited by 107
Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update
Novikov, A., & Vallon, V. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000187 · Cited by 114
Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes
Plosker, G. L. (2014) · Drugs · doi:10.1007/s40265-014-0324-3 · Cited by 114
“SGLT2 inhibitors also increase glucagon secretion, which in turn increases endogenous glucose production and may interfere with glucose control, as suggested in studies in patients with type 2 diabetes [18, 19] and from preclinical studies showing that SGLT2 inhibition triggers glucagon secretion in pancreatic alpha c…”
BackgroundSGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
Filippatos, T. D., Liontos, A., Papakitsou, I., & Elisaf, M. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1581971 · Cited by 118
Phrueksotsai, S., Pinyopornpanish, K., Euathrongchit, J., Leerapun, A., Phrommintikul, A., Buranapin, S., Chattipakorn, N., & Thongsawat, S. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15580 · Cited by 103
Massimino, E., Izzo, A., Riccardi, G., & Della Pepa, G. (2021) · Cells · doi:10.3390/cells10081958 · Cited by 102
Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
Al Jobori, H., Daniele, G., Adams, J., Cersosimo, E., Solis-Herrera, C., Triplitt, C., DeFronzo, R. A., & Abdul-Ghani, M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01838 · Cited by 103
Self-citationTherapeutic Manipulation of Myocardial Metabolism
Honka, H., Solis‐Herrera, C., Triplitt, C. L., Norton, L., Butler, J., & DeFronzo, R. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.057 · Cited by 108
Self-citationMolecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
Hou, Y., Zheng, C., Yen, T., & Lu, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217833 · Cited by 124
Suga, T., Kikuchi, O., Kobayashi, M., Matsui, S., Yokota‐Hashimoto, H., Wada, E., Kohno, D., Sasaki, T., Takeuchi, K., Kakizaki, S., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.10.009 · Cited by 111
Esterline, R. L., Vaag, A., Oscarsson, J., & Vora, J. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0832 · Cited by 98
Wei, R., Cui, X., Feng, J. B., Gu, L., Lang, S., Wei, T., Yang, J., Liu, J., Le, Y., Wang, H., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154324 · Cited by 108
Yabe, D., Nishikino, R., Kaneko, M., Iwasaki, M., & Seino, Y. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1034105 · Cited by 103
SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
Saucedo‐Orozco, H., Voorrips, S. N., Yurista, S. R., de Boer, R. A., & Westenbrink, B. D. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.1.1 · Cited by 117
Empagliflozin in the treatment of type 2 diabetes: evidence to date
Shubrook, J. H., Baradar-Bokaie, B., & Adkins, S. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s69926 · Cited by 112
“Finally, Phase III studies with EMPA have shown reductions in plasma uric acid.(33,35,37) This may be clinically important in that hyperuricemia has been identified as an independent risk factor for cardiovascular disease.”
Zhang, J., Chen, M., Chen, J., Lin, S., Cai, D., Chen, C., & Chen, Z. (2017) · Bioscience Reports · doi:10.1042/bsr20170036 · Cited by 101
Yaribeygi, H., Sathyapalan, T., Maleki, M., Jamialahmadi, T., & Sahebkar, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2019.117090 · Cited by 94
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Zou, H., Zhou, B., & Xu, G. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0547-1 · Cited by 91
The Role of α-Cells in Islet Function and Glucose Homeostasis in Health and Type 2 Diabetes
Gilon, P. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.004 · Cited by 92
SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
Garofalo, C., Borrelli, S., Liberti, M., Andreucci, M., Conte, G., Minutolo, R., Provenzano, M., & Nicola, L. D. (2019) · Medicina · doi:10.3390/medicina55060268 · Cited by 106
Gupta, P., Bala, M., Gupta, S. K., Dua, A., Dabur, R., Injeti, E. R., & Mittal, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.029 · Cited by 101
Miller, S., Krumins, T., Zhou, H., Huyck, S., Johnson, J., Golm, G., Terra, S. G., Mancuso, J. P., Engel, S. S., & Lauring, B. (2018) · Diabetes Therapy · doi:10.1007/s13300-017-0358-0 · Cited by 87
“Recent small mechanistic studies have suggested that SGLT2 inhibition may lead to increased insulin sensitivity and improved bcell function [31, 32].”
BackgroundWhat does sodium‐glucose co‐transporter 1 inhibition add: Prospects for dual inhibition
Rieg, J. A. D., & Rieg, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13630 · Cited by 93
Min, S. H., Yoon, J., Hahn, S., & Cho, Y. M. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2818 · Cited by 85
Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Plosker, G. L. (2014) · Drugs · doi:10.1007/s40265-014-0225-5 · Cited by 93
“In addition, the observed bodyweight loss from SGLT2 inhibitors is lower than that expected from sustained energy loss via increased glucosuria, which may be a consequence of compensatory hyperphagia (as suggested in a rat model [49]) and/or increased endogenous glucose production resulting from increased glucagon sec…”
BackgroundNovel agents for the treatment of type 2 diabetes
DeFronzo, R. A., Triplitt, C. L., Abdul-Ghani, M., & Cersosimo, E. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.100 · Cited by 83
Self-citationKashiwagi, A., & Maegawa, H. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12644 · Cited by 82
Horton, W. B., Love, K. M., Gregory, J. M., Liu, Z., & Barrett, E. J. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00826.2024 · Cited by 107
Kaneto, H., Obata, A., Kimura, T., Shimoda, M., Okauchi, S., Shimo, N., Matsuoka, T., & Kaku, K. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12494 · Cited by 92
“Insulin-mediated tissue glucose disposal was increased after 2 weeks treatment with dapagliflozin.(44) Interestingly, dapagliflozin treatment increased”
BackgroundInfluentialThe Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Patel, D. K., & Strong, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00686-z · Cited by 79
Cardiovascular Disease in Diabetes and Chronic Kidney Disease
Swamy, S., Noor, S. M., & Mathew, R. O. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12226984 · Cited by 96
“Sodium/glucose cotransporter 2 (SGLT2) inhibitors prevent glucose reabsorption in the proximal tubules of the kidney and lower the threshold for glucose excretions, leading to a negative sodium and water balance and an ultimate reduction in blood pressure [49,50].”
BackgroundInsulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
Abdul‐Ghani, M. A., Jayyousi, A., DeFronzo, R. A., Asaad, N., & Suwaidi, J. M. S. A. (2017) · Current Vascular Pharmacology · doi:10.2174/1570161115666171010115119 · Cited by 82
Self-citationRossing, P. R., Inzucchi, S. E., Vart, P., Jongs, N., Docherty, K. F., Jhund, P. S., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P. P., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00295-3 · Cited by 90
Glucagon and heart in type 2 diabetes: new perspectives
Ceriello, A., Genovese, S., Mannucci, E., & Gronda, E. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0440-3 · Cited by 77
“Also, DPP4i increase insulin secretion and decrease glucagon; so, potentially they block the compensatory EGP seen with SGLT-2i and increase their glucose-lowering capacity [38, 41, 42].”
BackgroundInzucchi, S. E., Docherty, K. F., Køber, L., Kosiborod, M., Martínez, F. A., Ponikowski, P. P., Sabatine, M. S., Solomon, S. D., Verma, S., Bělohlávek, J., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1675 · Cited by 80
Pharmacological aspects of the safety of gliflozins
Faillie, J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.001 · Cited by 81
“56,57 The hyperglucagonemia can be explained by i) the decreased levels of insulin which, in the pancreatic islets, exerts a inhibitory effect on glucagon release 58 and/or ii) the direct inhibition of SGLT2 transporter which, located in the membrane of alpha cells, is thought to play a role in…”
Jobori, H. A., Daniele, G., Adams, J. M., Cersósimo, E., Triplitt, C. L., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12881 · Cited by 86
Self-citationNo direct effect of SGLT2 activity on glucagon secretion
Kuhre, R. E., Ghiasi, S. M., Adriaenssens, A. E., Wewer Albrechtsen, N. J., Andersen, D. B., Aivazidis, A., Chen, L., Mandrup-Poulsen, T., Ørskov, C., Gribble, F. M., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4849-6 · Cited by 74
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes
Abdul-Ghani, M. A., Maffei, P., & DeFronzo, R. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00127-x · Cited by 89
Self-citationIkeda, S., Takano, Y., Cynshi, O., Tanaka, R., Christ, A. D., Boerlin, V., Beyer, U., Beck, A., Ciorciaro, C., Meyer, M., et al. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12538 · Cited by 73
Kaneto, H., Kimura, T., Obata, A., Shimoda, M., & Kaku, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052596 · Cited by 90
Michel, M. C., Mayoux, E., & Vallon, V. (2015) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-015-1134-1 · Cited by 78
“…and diabetic Tallyho/JngJ mice (Neschen et al. 2015) and with dapagliflozin in insulin-resistant mice (Bonner et al. 2015) and in diabetic patients (Merovici et al. 2014), a single dose or a 4-week treatment with empagliflozin increased endogenous glucose production accompanied by elevated plasma…”
BackgroundAnti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance
Hattori, S. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0395-5 · Cited by 72
Deng, L., Yang, Y., & Xu, G. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159234 · Cited by 88
Swe, M. T., Thongnak, L., Jaikumkao, K., Pongchaidecha, A., Chatsudthipong, V., & Lungkaphin, A. (2019) · Clinical Science · doi:10.1042/cs20190863 · Cited by 73
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
Scheen, A. J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1100167 · Cited by 70
“[94] Indeed, serum glucagon concentrations were increased in patients treated with SGLT2 inhibitors, an effect that could contribute not only to increase hepatic glucose production [95,96] but also ketogenesis in conditions of low insulin concentrations.”
BackgroundSeko, Y., Sumida, Y., Sasaki, K., Itoh, Y., Iijima, H., Hashimoto, T., Ishii, S., & Inagaki, N. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1364-8 · Cited by 70
New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
Dekkers, C. C. J., Gansevoort, R. T., & Heerspink, H. J. L. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0992-6 · Cited by 82
Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research
Beitelshees, A. L., Leslie, B. R., & Taylor, S. I. (2019) · Diabetes · doi:10.2337/dbi18-0006 · Cited by 78
AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69
SGLT2 inhibitors: are they safe?
Filippas-Ntekouan, S., Filippatos, T. D., & Elisaf, M. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1394152 · Cited by 80
Yabe, D., Iwasaki, M., Kuwata, H., Haraguchi, T., Hamamoto, Y., Kurose, T., Sumita, K., Yamazato, H., Kanada, S., & Seino, Y. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12848 · Cited by 67
Leccisotti, L., Cinti, F., Sorice, G. P., D’Amario, D., Lorusso, M., Guzzardi, M. A., Mezza, T., Gugliandolo, S., Cocchi, C., Capece, U., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01607-4 · Cited by 74
Cardiovascular impact of drugs used in the treatment of diabetes
Triggle, C. R., & Ding, H. (2014) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622314546125 · Cited by 67
Al-Jobori, H., Daniele, G., Cersosimo, E., Triplitt, C., Mehta, R., Norton, L., DeFronzo, R. A., & Abdul-Ghani, M. (2017) · Diabetes · doi:10.2337/db17-0100 · Cited by 67
Self-citationPancreatic α-cells – The unsung heroes in islet function
Wendt, A., & Eliasson, L. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.01.006 · Cited by 88
SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids
Filippas-Ntekouan, S., Tsimihodimos, V., Filippatos, T. D., Dimitriou, T., & Elisaf, M. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1541348 · Cited by 71
Cho, Y. K., Kang, Y. M., Lee, S. E., Lee, J. H., Park, J.-Y., Lee, W. J., Kim, Y. J., & Jung, C. H. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.01.011 · Cited by 70
Pedersen, M. G., Ahlstedt, I., El Hachmane, M. F., & Göpel, S. O. (2016) · Scientific Reports · doi:10.1038/srep31214 · Cited by 64
“It has been demonstrated that two chemically unrelated SGLT2 blockers, dapagliflozin and empagliflozin, despite their glucose lowering effect, increase plasma glucagon levels and raise endogenous glucose production in diabetic subjects 23,24 .”
Chae, H., Augustin, R., Gatineau, E., Mayoux, E., Bensellam, M., Antoine, N., Khattab, F., Lai, B.-K., Brusa, D., Stierstorfer, B., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101071 · Cited by 63
Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
Reed, J. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s111991 · Cited by 64
Gamede, M. W., Mabuza, L. P., Ngubane, P. S., & Khathi, A. (2018) · Molecules · doi:10.3390/molecules23040794 · Cited by 77
Hansen, L., Iqbal, N., Ekholm, E., Cook, W., & Hirshberg, B. (2014) · Endocrine Practice · doi:10.4158/ep14489.or · Cited by 65
den Kamp, Y. J. M. O., de Ligt, M., Dautzenberg, B., Moonen‐Kornips, E., ESTERLINE, R. L., Hesselink, M. K. C., Hoeks, J., Schrauwen‐Hinderling, V. B., Havekes, B., Oscarsson, J., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2887 · Cited by 71
Ketones: the double-edged sword of SGLT2 inhibitors?
Lupsa, B. C., Kibbey, R. G., & Inzucchi, S. E. (2022) · Diabetologia · doi:10.1007/s00125-022-05815-1 · Cited by 76
Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells
Solini, A., Sebastiani, G., Nigi, L., Santini, E., Rossi, C., & Dotta, F. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.04.002 · Cited by 65
SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms
Filippatos, T. D., Tsimihodimos, V., Liamis, G. L., & Elisaf, M. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.08.003 · Cited by 70
Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics
Ferrannini, E., Murthy, A. C., Lee, Y.-H., Muscelli, E., Weiss, S., Ostroff, R. M., Sattar, N., Williams, S. A., & Ganz, P. (2020) · Diabetes Care · doi:10.2337/dc20-0456 · Cited by 61
Horie, I., Abiru, N., Hongo, R., Nakamura, T., Ito, A., Haraguchi, A., Natsuda, S., Sagara, I., Ando, T., & Kawakami, A. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.11.016 · Cited by 67
Li, D., Shi, W., Wang, T., & Tang, H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13294 · Cited by 65
The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition
Capozzi, M. E., Coch, R. W., Koech, J., Astapova, I. I., Wait, J. B., Encisco, S. E., Douros, J. D., EL, K. M., Finan, B., Sloop, K. W., et al. (2020) · Diabetes · doi:10.2337/db19-1216 · Cited by 68
Willecke, F., Scerbo, D. A., Nagareddy, P. R., Obunike, J. C., Barrett, T. J., Abdillahi, M., Trent, C. M., Huggins, L. A., Fisher, E. A. A., Drosatos, K., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304615 · Cited by 68
“out affecting insulin levels in streptozotocin-diabetic mice, although we cannot rule out changes in insulin signaling.(45) Both the pharmacological inhibition by dapagliflozin and anti-”
Okamoto, A., Yokokawa, H., Sanada, H., & Naito, T. (2016) · Drugs in R&D · doi:10.1007/s40268-016-0137-9 · Cited by 59
Min, S. H., Yoon, J., Moon, S. J., Hahn, S., & Cho, Y. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-22658-2 · Cited by 74
Novel antidiabetic medications for non‐alcoholic fatty liver disease with type 2 diabetes mellitus
Sumida, Y., Seko, Y., Yoneda, M., & Japan Study Group of NAFLD (JSG‐NAFLD) (2017) · Hepatology Research · doi:10.1111/hepr.12856 · Cited by 60
Lee, S. A., & Riella, L. V. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.02.1435 · Cited by 71
“67,68 Because elevated insulin levels and insulin resistance can induce in fl ammation, mitochondrial dysfunction, mesangial proliferation, and dysfunction of podocytes and endothelial cells in kidneys, 69 the impact of SGLT2 inhibitors on insulin level and peripheral insulin sensitivity may offer a…”
BackgroundPowell, D. R., Zambrowicz, B., Morrow, L., Beysen, C., Hompesch, M., Turner, S., Hellerstein, M., Banks, P., Strumph, P., & Lapuerta, P. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz258 · Cited by 58
ElMahdy, M. K., Helal, M. G., & Ebrahim, T. M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106730 · Cited by 63
Bea, S., Ko, H. Y., Bae, J. H., Cho, Y. M., Chang, Y., Ryu, S., Byrne, C. D., & Shin, J. (2024) · Gut · doi:10.1136/gutjnl-2024-332687 · Cited by 68
“of GLP-1RA and glucose-dependent insulinotropic polypeptide receptor agonists and/or glucagon receptor agonists.”
Kadowaki, T., Inagaki, N., Kondo, K., Nishimura, K., Kaneko, G., Maruyama, N., Nakanishi, N., Iijima, H., Watanabe, Y., & Gouda, M. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12898 · Cited by 57
Busch, R. S., & Kane, M. P. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1342509 · Cited by 57
Sodium–Glucose Cotransporter–2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes
Kramer, C. K., & Zinman, B. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-042017-094221 · Cited by 62
Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets
Saponaro, C., Mühlemann, M., Acosta-Montalvo, A., Piron, A., Gmyr, V., Delalleau, N., Moerman, E., Thévenet, J., Pasquetti, G., Coddeville, A., et al. (2020) · Diabetes · doi:10.2337/db19-0888 · Cited by 61
Takahara, M., Shiraiwa, T., Matsuoka, T., Katakami, N., & Shimomura, I. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej14-0335 · Cited by 58
Kramer, C. K., Zinman, B., Choi, H., Connelly, P. W., & Retnakaran, R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2725 · Cited by 54
Primordial Drivers of Diabetes Heart Disease: Comprehensive Insights into Insulin Resistance
Fan, Y., Yan, Z., Li, T., Li, A., Fan, X., Qi, Z., & Zhang, J. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0110 · Cited by 67
Dapagliflozin for the treatment of type 2 diabetes: a review of the literature
Narendran, P., & Saeed, M. A. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s50963 · Cited by 71
“Recent data(36) indicate that SGLT2 is also expressed in human pancreatic α-cells, and therapy with dapagliflozin is described to increase circulating glucagon.(37) This increased glucagon potentially dampens the efficacy of SGLT2 inhibitors and needs further examination.”
DeFronzo, R. A., CHILTON, R. J., Norton, L., Clarke, G., Ryder, R. E. J., & Abdul‐Ghani, M. A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12652 · Cited by 55
Self-citationMARTINEZ, R. A., Jobori, H. A., Ali, A. M., Adams, J. M., Abdul-Ghani, M. A., Triplitt, C. L., DeFronzo, R. A., & Cersósimo, E. (2018) · Diabetes · doi:10.2337/db17-1278 · Cited by 57
Self-citationWang, M.-Y., Zhang, Z., Zhao, S., Onodera, T., Sun, X.-N., Zhu, Q., Li, C., Li, N., Chen, S., Paredes, M., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.024 · Cited by 52
Blonde, L., Belousova, L., Fainberg, U., Garcia‐Hernandez, P. A., Jain, S. M., Kaltoft, M. S., Mosenzon, O., Nafach, J., Palle, M. S., & Rea, R. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13978 · Cited by 54
Metabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition
Kogot‐Levin, A., Riahi, Y., Abramovich, I., Mosenzon, O., Agranovich, B., Kadosh, L., Schyr, R. B., Kleiman, D., Hinden, L., Cerasi, E., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.164296 · Cited by 53
Bjornstad, P., & Cherney, D. Z. I. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0996-2 · Cited by 57
Metadata
- Authors
- Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., & DeFronzo, R. A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, Ralph A.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-01-27
- Volume
- 124
- Issue
- 2
- Pages
- 509-514
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3904617
- OpenAlex
- W2166613497
- Cited by
- 795
- References
- 28
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 52 · 2023: 55 · 2022: 64 · 2021: 58 · 2020: 91 · 2019: 63 · 2018: 71 · 2017: 71 · 2016: 79 · 2015: 82 · 2014: 43
- FWCI
- 73.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- National Institutes of Health (UL1TR001120, 5R01DK240923, KL2TR001118)
- University of Texas Health Science Center at San Antonio
- National Institute of Diabetes and Digestive and Kidney Diseases (5R01DK240923, R01DK024092)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, skeletal muscle insulin sensitivity, endogenous glucose production, glycosuria, glucotoxicity, hyperglycemia, insulin-stimulated glucose disposal, glucagon, renal glucose transport
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Fasting, Glucagon, Glucose, Glucosides, Humans, Hyperglycemia, Insulin, Male, Metformin, Middle Aged, Muscles, Sulfonylurea Compounds, Time Factors, Glucose Clamp Technique, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.